Immuno-Oncology Biotech BriaCell Attracts Top Scientist to Head R&D

VANCOUVER, BC--(Marketwired - July 15, 2015) - BriaCell Therapeutics Corp (OTCQB: ANCCF) (TSX VENTURE: BCT) ("BriaCell", the "Company", or "BCT") announced today that Markus Lacher, Ph.D. has been appointed as Senior Director, Research and Development. Dr. Lacher will immediately assume all responsibility for the development and execution of all research and process development plans for the Company's lead product, BriaVax™, a cell-based cancer immunotherapy. In addition, Dr. Lacher will also assume responsibility for analyzing samples obtained from patients treated in the Company's upcoming Phase I/II clinical trial. Having served in a senior scientific role in the development programs of numerous cell therapy and diagnostic products, Dr. Lacher brings to BriaCell extensive experience within the biotechnology industry.

"It is an enormous honor for me to lead the research and development activities at BriaCell," said Dr. Lacher. "It not only allows me to further embrace my passionate belief in the promise of cancer immunotherapy but also to work with an outstanding team motivated to rapidly advance BriaCell's technology. In addition, I am particularly excited to work with Joseph Wagner in his mission to lead the BriaCell team in becoming a market leader for immunotherapy. I have known Joe for several years and have witnessed first hand how swiftly he combines his impressive science and business knowledge in order to reach corporate milestones. Finally, through my background in the field of prostate cancer immunotherapy, I recognize the value of BriaCell's core technology, which is, in essence, a clever way to educate the patient's immune system on how to recognize cancer cells."

"Over the course of my career in the biotechnology industry I have learned that, at the end of the day, one of the most critical elements for corporate success is choosing the right team," said Joseph Wagner, Ph.D., President and CEO of BriaCell. "Having worked with him at my previous company, I can truly say that Markus' scientific background, his endless energy and enthusiasm and his keen insight into the immune system make him such a perfect fit for BriaCell that I could not image finding a better person to lead our research efforts. This strategic expansion of the BriaCell team is timed to coincide with the manufacturing, testing and releasing of BriaVax for our upcoming clinical trial which is on track to begin in the early-Q4 time frame."

Dr. Lacher received his Ph.D. from the University of Bern (Switzerland) in 2001 and thereafter spent approximately eight years as a researcher at the University of California, San Francisco (UCSF). From 2009 to 2014 he worked at BioTime, Inc. and it's subsidiary OncoCyte Corporation where he developed key components of OncoCyte's therapeutic and diagnostic technology while working directly with Dr. Joseph Wagner. Immediately prior to joining BriaCell, Dr. Lacher was a Senior Clinical Scientist at Cesca Therapeutics, Inc., a clinical-stage autologous cell therapy company. Dr. Lacher is an author on numerous peer reviewed publications and a named inventor on multiple patent applications in the areas of cancer therapeutics and diagnostics. He is member of several scientific organizations and is on the editorial advisory board of the journal Recent Patents on Anti-Cancer Drug Discovery.

ABOUT BRIACELL
BriaCell is a breast cancer immunotherapy biotechnology company. Immunotherapies have come to the forefront of the fight against cancer, because they harness the body's own immune system in recognizing and selectively destroying the cancer cells, sparing normal ones. Immunotherapies are believed to be a more targeted, less toxic approach to managing cancer. This approach is also more likely to prevent recurrence and is not expected to produce the serious side effects seen with chemotherapy.

The Company has demonstrated unique and unprecedented results, and is intent on building upon these results to further advance BriaVax™ through the FDA Clinical Trials in order to help cancer patients with no other options. The results of two FDA Phase I clinical trials have been encouraging in terms of both safety and efficacy in patients with advanced, stage-IV breast cancer. Most uniquely, BriaCell has achieved these results in patients who had prior failed the available therapies including various kinds of chemotherapy. In some cases, the lifespan was three to five times longer than expected. The results were targeted, with little to no side effects, and were achieved rapidly, with regression occurring within 6 weeks.

In one patient, cancer regressed in all sites to which the cancer had spread, including lesions in the breast, lung, and even brain. This result was the most unique finding, given that the brain is largely considered an untouchable site in terms of cancer regression. Again, results were seen rapidly and with little to no adverse side effects.

The Company is planning to advance its cancer immunotherapy technology in an FDA Phase I/II clinical trial with up to 24 breast cancer patients with advanced stages of solid tumors. The FDA-approved protocol has provision to allow testing the vaccine in selected patients with other cancers as well, including prostate, ovarian, pancreas, lung and bladder cancers among others. Although the focus of the Company is currently breast cancer, it recognizes that upon further proof of concept, its technology may be applicable to such other cancers as well. For further information, please refer to Company's website at www.briacell.com or its youtube channel www.youtube.com/watch?v=el-yFF1uHoQ

The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.

Image Available: http://www.marketwire.com/library/MwGo/2015/7/15/11G047658/Images/BriaCell_-_Highlights_-_One_Pager-1315789228665-783710512986.jpg

Embedded Video Available: https://www.youtube.com/watch?v=el-yFF1uHoQ

Attachment Available: http://www.marketwire.com/library/MwGo/2015/7/15/11G047658/BriaCell_-_Highlights-120191398917-274725590219.pdf